Bacterial-mucosal interactions in inflammatory bowel disease-an alliance gone bad

被引:80
作者
Chichlowski, Maciej [1 ]
Hale, Laura P. [1 ]
机构
[1] Duke Univ, Med Ctr, DUMC 3712, Dept Pathol, Durham, NC 27710 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2008年 / 295卷 / 06期
基金
美国国家卫生研究院;
关键词
enteric bacteria; permeability; inflammation;
D O I
10.1152/ajpgi.90516.2008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The complex interaction of genetic, microbial, and environmental factors may result in continuous activation of the mucosal immune system leading to inflammatory bowel disease (IBD). Most present treatments for IBD involve altering or suppressing the aberrant immune response; however, the role of the intestinal microbiota in the pathophysiology of IBD is becoming more evident. The epithelial layer is essential for the proper functioning of the gastrointestinal tract, and its increased permeability to the luminal antigens may lead to the inflammatory processes and mucosal damage observed in IBD. Factors affecting the efficacy of the epithelial barrier include presence of pathogenic bacteria (e.g., Helicobacter spp.), presence of probiotic bacteria, availability of selected nutrients, and others. Defective function of the mucosal barrier might facilitate the contact of bacterial antigens and adjuvants with innate and adaptive immune cells to generate prolonged inflammatory responses. This review will briefly describe the complex structure of the epithelial barrier in the context of bacterial-mucosal interactions observed in human IBD and mouse models of colitis.
引用
收藏
页码:G1139 / G1149
页数:11
相关论文
共 123 条
[1]   Bacterial penetration of the mucosal barrier by targeting lipid rafts [J].
Abraham, SN ;
Duncan, MJ ;
Li, GJ ;
Zaas, D .
JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (06) :318-321
[2]   Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans [J].
An, Guangyu ;
Wei, Bo ;
Xia, Baoyun ;
McDaniel, J. Michael ;
Ju, Tongzhong ;
Cummings, Richard D. ;
Braun, Jonathan ;
Xia, Lijun .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (06) :1417-1429
[3]  
AONO S, 2004, EXPL CELL R IN PRESS
[4]   Biologic therapy for inflammatory bowel disease [J].
Ardizzone, S ;
Porro, GB .
DRUGS, 2005, 65 (16) :2253-2286
[5]   Recent advances in basic and clinical aspects of inflammatory bowel disease: Which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease? [J].
Asakura, Hitoshi ;
Suzuki, Kenji ;
Honma, Terasu .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (15) :2145-2149
[6]   EXPRESSION OF HUMAN MUCIN GENES IN RESPIRATORY, DIGESTIVE, AND REPRODUCTIVE TRACTS ASCERTAINED BY IN-SITU HYBRIDIZATION [J].
AUDIE, JP ;
JANIN, A ;
PORCHET, N ;
COPIN, MC ;
GOSSELIN, B ;
AUBERT, JP .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1993, 41 (10) :1479-1485
[7]   Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic [J].
Baorto, DM ;
Gao, ZM ;
Malaviya, R ;
Dustin, ML ;
vanderMerwe, A ;
Lublin, DM ;
Abraham, SN .
NATURE, 1997, 389 (6651) :636-639
[8]   CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease [J].
Barnich, Nicolas ;
Carvalho, Frederic A. ;
Glasser, Anne-Lise ;
Darcha, Claude ;
Jantscheff, Peter ;
Allez, Matthieu ;
Peeters, Harald ;
Bommelaer, Gilles ;
Desreumaux, Pierre ;
Colombel, Jean-Frederic ;
Darfeuille-Michaud, Arlette .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (06) :1566-1574
[9]   Rapid development of colitis in NSAID-treated IL-10-deficient mice [J].
Berg, DJ ;
Zhang, J ;
Weinstock, JV ;
Ismail, HF ;
Earle, KA ;
Alila, H ;
Pamukcu, R ;
Moore, S ;
Lynch, RG .
GASTROENTEROLOGY, 2002, 123 (05) :1527-1542
[10]   Improvement of the probiotic effect of micro-organisms by their combination with maltodextrins, fructo-oligosaccharides and polyunsaturated fatty acids [J].
Bomba, A ;
Nemcová, R ;
Gancarcíková, S ;
Herich, R ;
Guba, P ;
Mudronová, D .
BRITISH JOURNAL OF NUTRITION, 2002, 88 :S95-S99